Australia's Clarity Pharmaceuticals at over 2-year high as clinical trial begins
30/11/2023 24:09
** Shares of Australia's Clarity Pharmaceuticals CU6.AX
rise as much as 3.9% to A$1.350, hitting their highest level
since Sept 21, 2021
** The radio-pharmaceuticals co says it has started
Registrational Phase III CLARIFY trial for prostate cancer
** Says aim of the study is to assess the diagnostic
performance of Cu-SAR-bisPSMA, a molecule used for diagnostic
purposes, to detect high-risk prostate cancer
** Adds that as a registrational trial, the final study
results are intended to provide sufficient evidence to support
an application to the US FDA for approval
** Stock up 34.3% this year, as of last close
(Reporting by Nausheen Thusoo in Bengaluru)
((Nausheen.Thusoo@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial